Production (Stage)
Cytek Biosciences, Inc.
CTKB
$2.42
-$0.03-1.22%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 2.23% | 50.44% | 28.98% | -183.89% | -380.79% |
| Total Depreciation and Amortization | 10.37% | 13.65% | 17.36% | 44.22% | 65.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -37.41% | -29.46% | 23.66% | 16.09% | 4.15% |
| Change in Net Operating Assets | 172.00% | 173.39% | 182.16% | 104.00% | 60.19% |
| Cash from Operations | 233.81% | 380.57% | 1,576.55% | 1,284.50% | 180.83% |
| Capital Expenditure | 19.17% | 24.16% | 57.32% | 52.95% | 50.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -98.73% | 98.96% | 99.47% | 99.47% | 99.47% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -186.03% | -79.68% | 111.55% | 144.57% | 143.73% |
| Cash from Investing | -197.89% | 11.63% | 105.47% | 131.36% | 130.90% |
| Total Debt Issued | 149.43% | -- | -53.20% | -53.37% | -53.27% |
| Total Debt Repaid | -246.95% | 1.42% | -17.47% | -64.99% | -184.69% |
| Issuance of Common Stock | -37.89% | -18.18% | 1.07% | 18.91% | 37.98% |
| Repurchase of Common Stock | 26.62% | 50.27% | -409.22% | -3,491.71% | -16,689.85% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 27.91% | 62.16% | -991.63% | -1,098.01% | -880.71% |
| Foreign Exchange rate Adjustments | 20.07% | 413.63% | 234.91% | 255.15% | 139.82% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -300.95% | 47.76% | 99.25% | 121.24% | 115.97% |